Background: Reports from low- and middle-income countries (LMICs) indicate lower survival for children with medulloblastoma (MB), though these studies are mainly from single institutions or countries. This retrospective study aimed to analyze the outcomes for MB in 9 centers in 8 countries.
Methods: Patients <18 years with newly diagnosed MB, diagnosed between 2014 and 2018, were included. Clinical and biological characteristics were collected, and patient outcomes were analyzed.
Results: A total of 335 patients were included. The median age was 7.7 years, and 51 patients (15%) were <3 years old. Eighty-seven patients (26.0%) had experienced symptoms for more than 3 months before diagnosis. Of 326 (97.3%) patients who underwent resection, 153 (47%) had a gross total resection. Metastatic disease at diagnosis was identified in 82 patients (24.5%). Radiotherapy was administered to 213 patients (63.8%). A total of 117 deaths occurred, including 90 (76.9%) from tumor progression and 25 (21.4%) from surgical complications or infection. Sixty-three (18.9%) patients abandoned treatment. The 5-year event-free survival and overall survival (OS) were 43.8% ± 3.5% and 58.4% ± 3.7%, respectively. Younger age, presence of metastatic disease, and starting radiotherapy >42 days after diagnosis were not prognostic, while the degree of resection, presence of a severe infection, and a longer diagnostic interval were associated with worse outcomes.
Conclusions: This multinational cohort describes poor outcomes due to delays in care, high abandonment of treatment, surgical complications, and a low fraction of patients receiving radiotherapy. Interventions to build care capacity for children with MB in LMICs can be prioritized based on these data.
Keywords: global neuro-oncology; low- and middle-income countries; medulloblastoma; pediatric neuro-oncology.
© The Author(s) 2025. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.